Merit Medical Systems (NASDAQ:MMSI) Issues FY 2026 Earnings Guidance

Merit Medical Systems (NASDAQ:MMSI) updated its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 4.250-4.350 for the period, compared to the consensus earnings per share estimate of 3.980. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion.

Analyst Ratings Changes

MMSI has been the subject of a number of analyst reports. Canaccord Genuity Group set a $94.00 price target on shares of Merit Medical Systems in a report on Friday. BTIG Research boosted their price objective on Merit Medical Systems from $100.00 to $105.00 and gave the stock a “buy” rating in a research note on Friday. Needham & Company LLC upped their price objective on Merit Medical Systems from $90.00 to $101.00 and gave the company a “buy” rating in a research report on Friday. Compass Point set a $107.00 price objective on Merit Medical Systems in a research note on Monday, April 20th. Finally, Wells Fargo & Company lifted their target price on Merit Medical Systems from $74.00 to $83.00 and gave the stock an “equal weight” rating in a report on Friday. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Merit Medical Systems has an average rating of “Moderate Buy” and a consensus price target of $100.30.

Merit Medical Systems Trading Up 2.0%

Shares of MMSI traded up $1.66 during midday trading on Friday, hitting $85.01. The stock had a trading volume of 2,200,979 shares, compared to its average volume of 807,378. The stock’s 50 day moving average is $69.45 and its 200 day moving average is $71.69. The firm has a market cap of $5.07 billion, a PE ratio of 36.80, a price-to-earnings-growth ratio of 2.51 and a beta of 0.52. The company has a debt-to-equity ratio of 0.45, a current ratio of 5.08 and a quick ratio of 3.46. Merit Medical Systems has a 1 year low of $59.74 and a 1 year high of $94.75.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.23. The firm had revenue of $418.84 million during the quarter, compared to analysts’ expectations of $405.25 million. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.01 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. As a group, analysts forecast that Merit Medical Systems will post 3.62 EPS for the current fiscal year.

Insider Activity at Merit Medical Systems

In other Merit Medical Systems news, insider Brian G. Lloyd purchased 2,000 shares of Merit Medical Systems stock in a transaction dated Thursday, May 7th. The shares were purchased at an average cost of $62.62 per share, for a total transaction of $125,240.00. Following the completion of the acquisition, the insider owned 2,000 shares in the company, valued at $125,240. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Lynne N. Ward sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $62.61, for a total value of $313,050.00. Following the sale, the director directly owned 7,809 shares of the company’s stock, valued at $488,921.49. This represents a 39.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.70% of the stock is owned by insiders.

Merit Medical Systems News Roundup

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q2 results exceeded expectations. Merit reported revenue of $418.8 million, up 9.5% year over year and ahead of the $405.3 million consensus estimate. Non-GAAP EPS rose 18% to $1.19, versus expectations of $0.96 and the prior-year result of $1.01. GAAP operating margin improved to 14.4% from 12.3%, while non-GAAP operating margin increased to 22.6% from 21.2%. Merit Medical Reports Second Quarter 2026 Results
• Positive Sentiment: Management raised its full-year outlook. Merit now expects 2026 adjusted EPS of $4.25 to $4.35, above the approximately $3.98 analyst consensus, while maintaining revenue expectations near $1.6 billion. The upgrade reflects broad product growth, higher sales and expanding margins. MMSI Q2 Earnings and 2026 Guidance
• Positive Sentiment: Analysts increased their targets following the report. JPMorgan raised its target to $95 and assigned an Overweight rating; Needham lifted its target to $101 with a Buy rating; and BTIG increased its target to $105 with a Buy rating. These revisions reinforce optimism about Merit’s earnings trajectory. Analysts Increase Forecasts After Strong Q2 Results
• Neutral Sentiment: Wells Fargo also raised its target to $83 but retained an Equal Weight rating, indicating less upside than the more bullish analyst calls. With the shares trading near the mid-$80s and at a forward-looking premium valuation, further gains may depend on continued execution.
• Negative Sentiment: Year-to-date operating cash flow declined 11% to $110.0 million, while free cash flow fell 14% to $76.6 million, a potential concern despite the quarter’s stronger profitability.

Institutional Trading of Merit Medical Systems

Hedge funds and other institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC boosted its stake in shares of Merit Medical Systems by 7.3% during the first quarter. AQR Capital Management LLC now owns 16,361 shares of the medical instruments supplier’s stock valued at $1,730,000 after purchasing an additional 1,114 shares during the period. Goldman Sachs Group Inc. increased its stake in Merit Medical Systems by 16.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 719,313 shares of the medical instruments supplier’s stock worth $76,039,000 after buying an additional 103,878 shares during the period. EverSource Wealth Advisors LLC increased its stake in Merit Medical Systems by 745.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 922 shares of the medical instruments supplier’s stock worth $86,000 after buying an additional 813 shares during the period. First Trust Advisors LP lifted its holdings in Merit Medical Systems by 24.8% during the 2nd quarter. First Trust Advisors LP now owns 59,215 shares of the medical instruments supplier’s stock valued at $5,535,000 after buying an additional 11,770 shares in the last quarter. Finally, Cerity Partners LLC lifted its holdings in Merit Medical Systems by 9.1% during the 2nd quarter. Cerity Partners LLC now owns 3,019 shares of the medical instruments supplier’s stock valued at $282,000 after buying an additional 251 shares in the last quarter. Hedge funds and other institutional investors own 99.66% of the company’s stock.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.